Kingsview Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,093 shares of the bio

Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 15,732 shares of the biopharmaceut

Davidson Investment Advisors redujo su participación en Bristol Myers Squibb Company (NYSE:BMY - Free Report) en un 5,4% durante el segundo trimestre, según su presentación más reciente del Formulario 13F ante la Comisión de Bolsa y Valores (SEC). El inversor institucional poseía 277.201 acciones de la biofarmacéutica

Flputnam Investment Management Co. elevó su posición en acciones de Bristol Myers Squibb Company (NYSE:BMY - Free Report) en un 12,6% en el segundo trimestre, según la compañía en su presentación 13F más reciente ante la Comisión de Bolsa y Valores. La empresa poseía 236.011 acciones de la biofarmacéutica.

La expansión de Bristol Myers Squibb creará empleos con salarios altos y promoverá la innovación radiofarmacéutica en Indiana INDIANAPOLIS - El gobernador de Indiana, Mike Braun, anunció hoy que RayzeBio, Inc., una empresa de Bristol Myers Squibb, planea expandir significativamente su presencia en ciencias biológicas en Indiana, solidificando aún más la reputación del estado como la capital mundial de los radiofarmacéuticos. La compañía aumentará su inversión en sus operaciones de fabricación de radiofármacos, establecerá una nueva instalación en Whitestown y creará hasta 100 nuevos empleos con salarios altos en sus ubicaciones de Indianápolis y Whitestown planificadas para fines de 2029. “Como estado, estamos invirtiendo en nuestro sector de ciencias biológicas como nunca antes, con

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

Rakuten Investment Management Inc. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 334,982 shares of the biopharmaceutical company

Van ECK Associates Corp decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,217,590 shares of the biopharmaceuti

Kimelman & Baird LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 15,525 shares of the biopharmaceutical comp

Empowered Funds LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 239,727 shares of the biopharmaceutical company

Freestone Grove Partners LP bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 84,601 shares of the biopharmaceutic

Beacon Pointe Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 232,697 shares of the biopharmaceuti

Archer Investment Corp acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,272 shares of the biopharmaceutical co

Bristol-Myers Squibb (NYSE:BMY) presented new long term and real world data for Camzyos in obstructive hypertrophic cardiomyopathy at the European Society of Cardiology Congress. Five year results from the EXPLORER-LTE cohort highlighted sustained efficacy for oHCM patients with consistent improvements in functional capacity and symptoms. Real world evidence across global populations reported no new safety concerns and aligned with outcomes seen in clinical trials. The data set reinforces...

Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy for adults with relapsed or refractory multiple myeloma. The ZENBEXUS approval lands at a time when Bristol-Myers Squibb’s recent news flow also includes the end of its Cellares partnership for Breyanzi manufacturing and fresh questions around certain patent rights. Yet the share price has a 90-day return of 17.09% and a 1-year total shareholder return of 49.67%,...

Glenview Trust Co purchased a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 102,223 shares of the biopharmaceutical company

Public Employees Retirement System of Ohio bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 840,572 shares of the

United Capital Financial Advisors LLC acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 176,631 shares of the biopharmaceutical company

Jefferies Financial Group Inc. purchased a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 508,740 shares of the

Redwood Investment Management LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,992 shares of the biopharmaceutical company